SCHEMBL7104549

SCHEMBL7104549

COCCn1c(=O)c2cc(C(=O)NCc3ccc(OC)cc3)ccc2n(C)c1=O

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.53
KDM4E B2RXH2 4/20 0.53
GAA P10253 2/20 0.53
GLA P06280 1/20 0.53
SMN1; SMN2 Q16637 1/20 0.53
CYP2C9 P11712 2/20 0.53
HPGD P15428 2/20 0.53
CYP3A4 P08684 1/20 0.53
CYP2C19 P33261 1/20 0.53
MAPT P10636 6/20 0.53
MEN1 O00255 3/20 0.53
KMT2A Q03164 3/20 0.53
RECQL P46063 1/20 0.53
MMP13 P45452 2/20 0.52
RXFP1 Q9HBX9 2/20 0.52
POLB P06746 1/20 0.48
TP53 P04637 3/20 0.48
NPC1 O15118 1/20 0.47
EPHX2 P34913 1/20 0.47
RAB9A P51151 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7099302 0.92 MAPT (0.53) ALDH1A1KDM4ESMN1; SMN2CYP2C9HPGD
SCHEMBL6234634 0.91 MMP13 (0.58) ALDH1A1KDM4ESMN1; SMN2MAPTMEN1
SCHEMBL7021095 0.90 MAPT (0.51) ALDH1A1KDM4ECYP2C9HPGDMAPT
SCHEMBL7148722 0.90 MAPT (0.51) ALDH1A1KDM4ESMN1; SMN2CYP2C9HPGD
SCHEMBL6254390 0.90 MAPT (0.52) ALDH1A1KDM4EGAACYP2C9HPGD
SCHEMBL7627970 0.89 MAPT (0.52) ALDH1A1KDM4ESMN1; SMN2MAPTMEN1
SCHEMBL7192894 0.89 RXFP1 (0.51) ALDH1A1KDM4ESMN1; SMN2MAPTMEN1
SCHEMBL7623073 0.89 MAPT (0.54) ALDH1A1KDM4ESMN1; SMN2CYP2C9HPGD
SCHEMBL7627149 0.88 MAPT (0.51) ALDH1A1KDM4ECYP2C9HPGDMAPT
SCHEMBL6259580 0.87 MMP13 (0.61) ALDH1A1KDM4EMAPTMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1368324-A1 QUINAZOLINES AS MMP-13 INHIBITORS Warner-Lambert Company LLC (US) 2003-12-10 EP claimed
US-20020193377-A1 Quinazolines as MMP-13 inhibitors ANDRIANJARA CHARLES (FR) 2002-12-19 US claimed
WO-2002064572-A1 QUINAZOLINES AS MMP-13 INHIBITORS WARNER-LAMBERT COMPANY LLC (US) 2002-08-22 WO claimed
US-20020193377-A1 Quinazolines as MMP-13 inhibitors ANDRIANJARA CHARLES (FR) 2002-12-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020193377-A1 Quinazolines as MMP-13 inhibitors MMP13, MMP9, MMP3 ALDH1A1 1357/4885KDM4E 1784/4885GAA 2252/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.